four pages)------------------------------------------------ 6 Other Biographical Sketch-- (Not to exceed four pages for each -- (See instructions)------------------------------------------------------ 9 Resources-------------------------------------------------------------------------------------------------------------------------------------------------------- 16 Research Plan 18 A.
Specific Aims ------------------------------------------------------------------------------------------------------------------------------------ 18 B. Background and Significance-------------------------------------------------------------------------------------------------------------- 19 C. Preliminary Studies/Progress Report/ (Items A-D: not to exceed 25 pages*) 22 Phase I Progress Report (SBIR/STTR Phase II ONLY) *SBIR/STTR Phase I: Items A-D limited to 15 pages. D. Research Design and Methods------------------------------------------------------------------------------------------------------------ 33 E. Human Subjects-------------------------------------------------------------------------------------------------------------------------------- Protection of Human Subjects (Required if Item 4 on the Face Page is marked """"""""Yes"""""""") Inclusion of Women (Required if Item 4 on the Face Page is marked """"""""Yes"""""""")---------------------------------------------------- Inclusion of Minorities (Required if Item 4 on the Face Page is marked """"""""Yes"""""""")-------------------------------------------------- Inclusion of Children (Required if Item 4 on the Face Page is marked """"""""Yes"""""""")---------------------------------------------------- Data and Safety Monitoring Plan (Required if Item 4 on the Face Page is marked """"""""yes"""""""" and a Phase I, II, or III clinical trial is proposed) F. Vertebrate Animals---------------------------------------------------------------------------------------------------------------------------- 43 G. Literature---------------------------------------------------------------------------------------------------------------------------------------- 44 H. Consortium/Contractual Arrangements-------------------------------------------------------------------------------------------------- I. Letters of Support (e.g., Consultants)------------------------------------------------------------------------------------------------------ 50 J. Product Development Plan (SBIR/STTR Phase II and Fast-Track ONLY)------------------------------------------------------ Checklist---------------------------------------------------------------------------------------------------------------------------------------------------------- 54 Appendix (Five collated sets: No page numbering necessary for Appendix.) Check if Appendix is Appendices NOT PERMITTED for Phase I SBIR/STTR unless specifically solicited. Included Number of publications and manuscripts accepted for publication (not to exceed 10) Other items (list): PHS 398 (Rev. 05/01) Page 4

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL066088-10
Application #
7762787
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Liu, Lijuan
Project Start
2001-02-01
Project End
2010-08-19
Budget Start
2010-02-01
Budget End
2010-08-19
Support Year
10
Fiscal Year
2010
Total Cost
$262,534
Indirect Cost
Name
University of California Los Angeles
Department
Pathology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Tontonoz, Peter; Wu, Xiaohui; Jones, Marius et al. (2017) Long Noncoding RNA Facilitated Gene Therapy Reduces Atherosclerosis in a Murine Model of Familial Hypercholesterolemia. Circulation 136:776-778
Gao, Jie; Marosi, Mate; Choi, Jinkuk et al. (2017) The E3 ubiquitin ligase IDOL regulates synaptic ApoER2 levels and is important for plasticity and learning. Elife 6:
Sallam, Tamer; Jones, Marius C; Gilliland, Thomas et al. (2016) Feedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis. Nature 534:124-8
Ito, Ayaka; Hong, Cynthia; Oka, Kazuhiro et al. (2016) Cholesterol Accumulation in CD11c+ Immune Cells Is a Causal and Targetable Factor in Autoimmune Disease. Immunity 45:1311-1326
Tian, Xiao Yu; Ganeshan, Kirthana; Hong, Cynthia et al. (2016) Thermoneutral Housing Accelerates Metabolic Inflammation to Potentiate Atherosclerosis but Not Insulin Resistance. Cell Metab 23:165-78
Lee, Stephen D; Tontonoz, Peter (2015) Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 242:29-36
Warrier, Manya; Shih, Diana M; Burrows, Amy C et al. (2015) The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell Rep :
Ito, Ayaka; Hong, Cynthia; Rong, Xin et al. (2015) LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling. Elife 4:e08009
Choi, Jinkuk; Gao, Jie; Kim, Jaekwang et al. (2015) The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and A? amyloidosis. Sci Transl Med 7:314ra184
Calkin, Anna C; Lee, Stephen D; Kim, Jason et al. (2014) Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice. Circ Res 115:442-9

Showing the most recent 10 out of 61 publications